Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Allelic Variants Relate to Shifts in Faecal Microbiota of Cystic Fibrosis Patients

被引:81
|
作者
Schippa, Serena [1 ]
Iebba, Valerio [1 ]
Santangelo, Floriana [1 ]
Gagliardi, Antonella [1 ]
De Biase, Riccardo Valerio [2 ]
Stamato, Antonella [2 ]
Bertasi, Serenella [2 ]
Lucarelli, Marco [3 ]
Conte, Maria Pia [1 ]
Quattrucci, Serena [2 ]
机构
[1] Univ Roma La Sapienza, Microbiol Unit, Publ Hlth & Infect Dis Dept, Rome, Italy
[2] Univ Roma La Sapienza, Paediat & Infant Neuropsychiat Dept, Reg Cyst Fibrosis Ctr, Rome, Italy
[3] Univ Roma La Sapienza, Dept Haematol & Cellular Biotechnol, Rome, Italy
来源
PLOS ONE | 2013年 / 8卷 / 04期
关键词
16S RIBOSOMAL-RNA; PEDIATRIC-PATIENTS; GUT MICROBIOTA; BACTERIA; DISEASE; GENE; CONSEQUENCES; PATHOGENESIS; SEQUENCE; SAMPLES;
D O I
10.1371/journal.pone.0061176
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction: In this study we investigated the effects of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene variants on the composition of faecal microbiota, in patients affected by Cystic Fibrosis (CF). CFTR mutations (F508del is the most common) lead to a decreased secretion of chloride/water, and to mucus sticky secretions, in pancreas, respiratory and gastrointestinal tracts. Intestinal manifestations are underestimated in CF, leading to ileum meconium at birth, or small bowel bacterial overgrowth in adult age. Methods: Thirty-six CF patients, fasting and under no-antibiotic treatment, were CFTR genotyped on both alleles. Faecal samples were subjected to molecular microbial profiling through Temporal Temperature Gradient Electrophoresis and species-specific PCR. Ecological parameters and multivariate algorithms were employed to find out if CFTR variants could be related to the microbiota structure. Results: Patients were classified by two different criteria: 1) presence/absence of F508del mutation; 2) disease severity in heterozygous and homozygous F508del patients. We found that homozygous-F508del and severe CF patients exhibited an enhanced dysbiotic faecal microbiota composition, even within the CF cohort itself, with higher biodiversity and evenness. We also found, by species-specific PCR, that potentially harmful species (Escherichia coli and Eubacterium biforme) were abundant in homozygous-F508del and severe CF patients, while beneficial species (Faecalibacterium prausnitzii, Bifidobacterium spp., and Eubacterium limosum) were reduced. Conclusions: This is the first report that establishes a link among CFTR variants and shifts in faecal microbiota, opening the way to studies that perceive CF as a 'systemic disease', linking the lung and the gut in a joined axis.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Cystic fibrosis transmembrane conductance regulator (CFTR): beyond cystic fibrosis
    Parisi, Giuseppe Fabio
    Mollica, Federico
    Giallongo, Alessandro
    Papale, Maria
    Manti, Sara
    Leonardi, Salvatore
    [J]. EGYPTIAN JOURNAL OF MEDICAL HUMAN GENETICS, 2022, 23 (01)
  • [2] Cystic fibrosis transmembrane conductance regulator (CFTR): beyond cystic fibrosis
    Giuseppe Fabio Parisi
    Federico Mòllica
    Alessandro Giallongo
    Maria Papale
    Sara Manti
    Salvatore Leonardi
    [J]. Egyptian Journal of Medical Human Genetics, 23
  • [3] Identification of cystic fibrosis transmembrane conductance regulator gene (CFTR) variants
    Almaghamsi, Talal
    Attiyah, Wejdan Ba
    Bahasan, Mona
    Alotaibi, Badi A.
    Alahmadi, Shahad F.
    Hanbazazh, Mehenaz
    Zakariyah, Abeer
    Saleem, Rimah A.
    AlAnezi, Munaifah K.
    Hawsawi, Yousef
    [J]. SAUDI MEDICAL JOURNAL, 2023, 44 (10) : 987 - 994
  • [4] Reply to: Cystic fibrosis transmembrane conductance regulator (CFTR) variants and CFTR function in patients with pancreatitis
    Melotti, Paola
    Angyal, Dora
    Bijvelds, Marcel J. C.
    Frulloni, Luca
    [J]. PANCREATOLOGY, 2024, 24 (06) : 971 - 972
  • [5] CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR)
    HIGGINS, CF
    [J]. BRITISH MEDICAL BULLETIN, 1992, 48 (04) : 754 - 765
  • [6] Pharmacology of CFTR (cystic fibrosis transmembrane conductance regulator)
    Cuthbert, A. W.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 22 - 22
  • [7] Cystic fibrosis: bacterial pathogenesis and CFTR (cystic fibrosis transmembrane conductance regulator) modulators
    Vargas-Roldan, Silvia Y.
    Lezana-Fernandez, Jose L.
    Cerna-Cortes, Jorge F.
    Partida-Sanchez, Santiago
    Santos-Preciado, Jose, I
    Rosales-Reyes, Roberto
    [J]. BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, 2022, 79 (04): : 215 - 221
  • [8] Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis
    Fukuda, Ryosuke
    Okiyoneda, Tsukasa
    [J]. PHARMACEUTICALS, 2020, 13 (04)
  • [9] EPIGENETIC REGULATION OF AUTOPHAGY AND CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) FUNCTION IN CYSTIC FIBROSIS
    Amer, A.
    Tazi, M.
    Caution, K.
    [J]. PEDIATRIC PULMONOLOGY, 2015, 50 : 285 - 285
  • [10] Effects of cystic fibrosis transmembrane conductance regulator (CFTR)-modulating therapy on glucose metabolism in cystic fibrosis patients
    Yesquen, Pamela
    Campos, Ariadna
    Mogas, Eduard
    Yeste, Diego
    Gartner, Silvia
    Clemente, Maria
    [J]. HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (SUPPL 2): : 179 - 179